Key targets and new therapeutic approaches for Neuroblastoma: From the bench to the bedside.

Ce.S.I-MET, Research Institute, University of Chieti-Pescara

Via Dei polacchi 11,

66100 Chieti, Italy.

-------------------------------------------------------------------------------------------------------------

***Thursday, 15 February***

*-Arrival and registration: 15:00*

- 15:30 Conference opening and introduction to the CESI-Met institute (Vincenzo De Laurenzi)

- 15:40 Introduction to neuroblastoma (Arturo Sala)

**Immunotherapy I (Session chairs: Arturo Sala; V De Laurenzi)**

- 15:50 **Franco Locatelli**, Ospedale Bambin Gesu’. Development of a third-generation GD2-specific CAR construct to treat children with neuroblastoma

- 16:30 **Loredana Cifaldi**, Ospedale Bambin Gesu’. Boosting Natural Killer cell-based immunotherapy of high-risk neuroblastoma: new molecular strategies

- 16:55 **Doriana Fruci**, Ospedale Bambin Gesu’. Immune microenvironment in neuroblastoma: clinical and therapeutic relevance

- 17:20 **Keynote speaker**: **Waseem Qasim**, UCL Institute of Child Health. Gene edited T cells for leukaemia

* *18:00 Welcome Cocktail.*

*- 19:00 Bus to Hotel*

-------------------------------------------------------------------------------------------------------------

***Friday, 16th February***

-9:30 **Sara Costa**, Associazione Italiana per la Lotta al Neuroblastoma

**MYCN (Session Chair: Giovanni Perini, Giuseppe Giannini)**

-10:00 **Giovanni Perini**, Universita’ di Bologna. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma

-10:25 **Alexia Tsakaneli**, Brunel University London. MYCN regulates exosome protein cargo in neuroblastoma

-10:50 **Victor Corasolla Carregari**, Fondazione Santa Lucia. MYCN modulation of membrane proteins expression in neuroblastoma cell lines

*-11:15 Coffee break*

-11:45 **Marialaura Petroni**, Istituto Italiano di Tecnologia. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN amplified neuroblastoma

-12:05 **Valeria Colicchia**, Universita’ di Roma La Sapienza. Targeting the replication stress response by combined PARP and CHK1 inhibition: a new strategy to treat MYCN amplified neuroblastoma

*-12:30 Lunch*

**Small molecules and new targets (Session Chair: Mario Capasso, Michele Sallese)**

-13:30 **Paolo Ciufici**, Universita’ di Chieti-Pescara. A Molecularly driven pharmacological approach for neuroblastoma: targeting TERT and CKS1b

-13:55 **Sanja Aveic**, Pediatric Research Institute - Citta’ della Speranza, Padova. Autophagy block as an attempting approach to improve the cytotoxic effects of receptor tyrosine kinase inhibitors

-14:20 **Flora Cimmino**, Universita’ di Napoli. *FGFR1* N546K is oncogenic driver mutation in neuroblastoma

-14:45 **Francesca Broso**, Universita’ di Trento. A screening for natural products identifies a flavonol as a synergistic compound with 13-cis retinoic acid in neuroblastoma

-15:10 **Giuseppe Raschella**’, ENEA. ZNF281 controls neuroblastoma differentiation in a TAp73/miR34a/MYCN regulatory axis

-15:35 **Simona Cocchi**, Universita’ di Trento. Targeting the Lin28/let-7 axis by small molecules in neuroblastoma

*-16:00 Coffee break*

**Immuntherapy II (Session Chair: Vito Pistoia, Franco Locatelli)**

-16:20 **Gianluca Sala**, Universita’ di Chieti-Pescara; Mediapharma. Antibody Drug Conjugates for cancer therapy

-16:45 **Ignazio Caruana**, Ospedale Bambin Gesu’. Generation of T lymphocytes genetically modified to express third generation GD2-specific chimeric antigen receptor (CAR) with CD28/4.1BB costimulation to improve anti-tumour efficacy of adoptive T cell therapy for patients with neuroblastoma

-17:10 **Maria** **Valeria Corrias**, Ospedale Gaslini. Bone marrow disease in neuroblastoma

**-17:35 General discussion and concluding remarks**

*-18:15 Bus to hotel*

*-20:30 Gala Dinner, Restaurant “Le Terrazze”, Pescara.*